Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. UCB
  6. News
  7. Summary
    UCB   BE0003739530

UCB

(UCB)
  Report
Real-time Quote. Real-time Euronext Bruxelles - 06/22 11:35:13 am
84.52 EUR   -0.82%
06/18UCBá : Disposals of own shares
PU
06/16UCBá : Our Commitment to Changing the Status Quo in Psoriasis Care
PU
06/11UCBá : Disposals of own shares
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

UCB : Why UCB has made a science-based commitment to reducing …

05/11/2021 | 03:52am EDT

I don't have to tell you how incredibly important it is that we reduce greenhouse emissions. We're hearing and seeing the impact of climate change in the news almost every day. It's time to act.

And while we all understand that we need to play our part how do we make sure that any steps we take will sufficiently contribute to limiting global warming? How do we ensure we're making a real contribution towards our patients, our colleagues and society?

That's where the Science Based Targets initiative (SBTi) comes in. If you've not heard about it, let me fill you in. SBTi is a coalition that believes that involving businesses is key to tackling climate change. With that in mind, it is helping companies to set targets for reducing their greenhouse gas emissions.

The targets companies are setting through SBTi aren't just any targets; they are targets based on science. The SBTi considers targets to be 'science-based' if they are in line with the Paris Agreement, in other words keeping the rise in global temperature well below 2°C and pursuing efforts to limit the increase to 1.5 °C. And because those targets are based on science, companies can feel that the steps they are taking to reduce their emissions are having a real impact on climate change.

So, who's involved? Firstly, SBTi is a partnership between the Carbon Disclosure Project (CDP), the United Nations Global Compact, the World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). And more than 1,000 companies in a wide range of sectors and across the globe have now joined, each of us contributing and playing our part.

UCB's CO2e target aims to impact the operations we control directly as well as those of our suppliers and business partners.

You can find the targets we've set ourselves on the SBTi website :

  • UCB commits to reduce absolute scope 1, 2 and 3 GHG emissions 38% by 2030 from a 2015 base year. UCB also commits that 60% of its suppliers by emissions, will have science-based targets by 2025.
I am so glad that the SBTi has approved our ambitious targets. We're humbled to be one of only 22 companies in the Pharmaceuticals, Biotechnology and Life sector globally to have our targets validated by the SBTi.

But we felt reducing our emissions wasn't enough. We want to do more. And that's why we've also set ourselves targets to reduce water consumption by 20% and waste production by 25%. Take a peek at our health of the Planet strategy of our corporate website; you can read more about these and other targets.

Let's join together in caring for our planet in everything we do. Together, we must make a difference. Together, we can make a difference.

Disclaimer

UCB SA published this content on 11 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2021 07:51:00 UTC.


ę Publicnow 2021
All news about UCB
06/18UCBá : Disposals of own shares
PU
06/16UCBá : Our Commitment to Changing the Status Quo in Psoriasis Care
PU
06/11UCBá : Disposals of own shares
PU
06/11UCB @ AOEC 2021 : our commitment to women of childbearing age living with epilep..
AQ
06/08UCBá : Celebrates Patient Strength During MG Awareness Month
PU
06/04UCBá : Disposals of own shares
PU
06/01EULAR 2021 : New Data from UCB's Rheumatology Portfolio Demonstrates …
PU
05/25UCBá : Disposals of own shares
PU
05/25PRESS RELEASE : AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to C..
DJ
05/20CLINICAL TRIAL DAY : Honoring our Clinical Researchers
PU
More news
Financials
Sales 2021 5 511 M 6 579 M 6 579 M
Net income 2021 909 M 1 085 M 1 085 M
Net Debt 2021 725 M 866 M 866 M
P/E ratio 2021 17,6x
Yield 2021 1,55%
Capitalization 15 971 M 19 015 M 19 066 M
EV / Sales 2021 3,03x
EV / Sales 2022 3,01x
Nbr of Employees 8 096
Free-Float 59,2%
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 84,52 €
Average target price 103,97 €
Spread / Average Target 23,0%
EPS Revisions
Managers and Directors
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Sandrine Dufour Chief Financial Officer & Executive Vice President
Stefan Oschmann Chairman
Iris L÷w-Friedrich Chief Medical Officer & EVP-Development
Dhavalkumar Patel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
UCB0.88%19 184
CSL LIMITED7.89%104 503
WUXI BIOLOGICS (CAYMAN) INC.28.50%74 696
BIOGEN INC.55.56%57 348
SAMSUNG BIOLOGICS CO.,LTD.1.21%49 837
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.21.49%44 894